Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Lab-Based COVID-19 PCR Tests Fail to Distinguish New ‘Stealth’ Version of Omicron from Other Variants

By LabMedica International staff writers
Posted on 09 Dec 2021

Omicron, the new SARS-CoV-2 variant, lacks a specific feature that allows PCR tests to distinguish probable cases among COVID-19 positive individuals, according to a report by The Guardian. More...

Scientists claim to have identified a “stealth” version of Omicron that cannot be distinguished from other SARS-CoV-2 variants using PCR tests utilized by public health officials to gain an understanding of its spread globally. The first Omicron (B.1.1.529) case was reported to the World Health Organization (WHO) on November 24. Just two days later, the WHO designated the variant a Variant of Concern (VOC), based on its unusually large number of mutations and early evidence of its spread. Despite a series of rapidly implemented travel bans, it has now been reported in Africa, many European countries, and a few in Asian countries.

The newly-discovered variant of Omicron shares several mutations with the standard Omicron, but lacks a specific genetic change that allows probable cases to be flagged by lab-based PCR tests. Most PCR machines look for three genes in the virus, although Omicron (and the prior variant Alpha) test positive on only two of these machines due to a genetic change called a deletion in the “S” or spike gene in both Omicron and Alpha. As a result of this glitch, PCR tests that display the so-called “S gene target failure” are highly suggestive of Omicron infections. The commonly used tests can still detect the stealth variant of Omicron as coronavirus, and genomic testing can identify it as the Omicron variant, although routine PCR tests that deliver quicker results can fail to flag probable cases.

Following the discovery of the new form of the Omicron variant, researchers have now split the B.1.1.529 lineage into standard Omicron, known as BA.1, and the newer variant, known as BA.2. Some researchers have now termed the new variant as “stealth Omicron” due to its lack of deletion that allows it to be spotted by PCR tests. Despite falling under Omicron, the stealth variant is so genetically distinct that it could qualify as a new VOC if it spreads rapidly. Researchers are worried over the arrival of two variants, BA.1 and BA.2, in quick succession with shared mutations that could indicate public health surveillance “is missing a big piece of the puzzle”.


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
New
Hematology Consumables
Bioblood Devices
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.